Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies.
Although chronic lymphocytic leukemia (CLL) cells provide an excellent target for antibody therapy, to date this approach has met with limited success in patients with CLL. Promising data are emerging with a new generation of antibodies, such as Campath-1H, which may offer effective therapeutic options not only as single agents but also in combination with such drugs as fludarabine. Other new antibodies, including rituximab and several new radioimmunoconjugates, have provided impressive results in the indolent non-Hodgkin's lymphomas and warrant further investigation.
Rai
K R
KR
Division of Hematology/Oncology, Long Island Jewish Medical Center and Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA.
D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology*; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans
D000912:Antibodies, Neoplasm